new glp 1 med Professor Receives Grant to Study Effectiveness of GLP-1 Weight-Loss Drugs GLP-1 Medications Show Promise as

either those that inhibit haem-iron availability or bacterial acquisition pathways, or toxic haem/iron-mimicking compounds that gain entry to bacterial cells through existing uptake systems ( 5.1.1 Siderophore synthesis inhibitors One of the earliest antimicrobials used for tuberculosis treatment, para-aminosalicylic acid, inhibits synthesis of the bacterial siderophore, mycobactin (Ribeiro and Simes, 2019)

Phase 2 Trial Results: The Numbers Behind the Hype The Phase 2 data for Retatrutide was published in the New England Journal of Medicine and represents the most discussed set of results in obesity pharmacology in recent years

doi: 10.1111/imr.12977 55 KisselevaTBrennerD

Hussain R, Zubair H, Pursell S, Shahab M (2018) Neurodegenerative diseases: regenerative mechanisms and novel therapeutic approaches